1,2,3,4,5Department of Pharmacy, Prasad Institute of Technology, Jaunpur, India
1*Professor & Head, Email: piyush61184@gmail.com
2**Associate Professor, Email: manojniperrbl@gmail.com
3Associate Professor
4Assistant Professor
5Assistant Professor
In the fields of molecular medicine and gene therapy, one of the remaining challenges is the creation of safe and effective, non-viral gene delivery systems. The use of cationic lipids in transfection has been limited due to glycerol's hydrolytic instability and poor cellular uptake, as well as the dose-dependent, cytotoxic effects exhibited by the lipids. This study addresses the design and synthesis of a novel, stable and more biologically active vector to mitigate the consequences of using cationic lipids as transfection agents. The new vector was synthesized using a multi-step organic synthesis, with an amino alcohol as the central scaffold to give structural flexibility to the hydrophobic and cationic portions of the vector. The desired product was verified through structural analysis of FTIR, ¹H-NMR, and mass spectrometry. To the vector's design, more stable and active lipids' physicochemical proprieties were present, distinguished through an ideal particle size, optimally negative zeta potential, and a significant strong DNA affinity. In vitro transfection studies carried out in cultured mammalian cells offered an enhanced gene delivery over the standard glycerol transfection agents, revealing low cytotoxic consequences. These results showcase the potential of utilizing a non-glycerol framework as an additive in the formulation of enhanced cationic lipids with optimal charge ratio, enhanced biodegradability, and cellular compatibility. The overall synthesized vector represents safe and efficient non-viral splicing of nucleic acids for therapy.
Keywords: Non-viral vector, Non-glycerol lipid, Gene delivery, Cationic lipid, Transfection efficiency, Biocompatibility.
How to cite this article: Yadav P, Yadav MK, Maurya PD, Maurya P, Kumar R. Synthesis of Novel Non-Glycerol Based Transfection Vector. Int J Drug Deliv Technol. 2026;16(7s): 1030-1041; DOI: 10.25258/ijddt.16.7s.111
Source of support: None
Conflict of interest: None